World Investment Advisors Acquires Shares of 16,290 Guardant Health, Inc. $GH

World Investment Advisors bought a new stake in Guardant Health, Inc. (NASDAQ:GH) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 16,290 shares of the company’s stock, valued at approximately $1,664,000.

A number of other institutional investors and hedge funds have also modified their holdings of the stock. Vanguard Group Inc. lifted its stake in Guardant Health by 2.1% in the 4th quarter. Vanguard Group Inc. now owns 12,160,768 shares of the company’s stock valued at $1,242,101,000 after buying an additional 251,939 shares in the last quarter. Price T Rowe Associates Inc. MD increased its stake in Guardant Health by 33.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 5,636,078 shares of the company’s stock worth $575,670,000 after buying an additional 1,414,441 shares in the last quarter. Franklin Resources Inc. increased its stake in Guardant Health by 14.9% during the 4th quarter. Franklin Resources Inc. now owns 3,361,547 shares of the company’s stock worth $343,348,000 after buying an additional 435,232 shares in the last quarter. Geode Capital Management LLC raised its holdings in shares of Guardant Health by 9.4% during the fourth quarter. Geode Capital Management LLC now owns 3,213,657 shares of the company’s stock valued at $328,297,000 after acquiring an additional 277,001 shares during the last quarter. Finally, Fuller & Thaler Asset Management Inc. raised its holdings in shares of Guardant Health by 3.0% during the fourth quarter. Fuller & Thaler Asset Management Inc. now owns 2,441,730 shares of the company’s stock valued at $249,398,000 after acquiring an additional 72,162 shares during the last quarter. Hedge funds and other institutional investors own 92.60% of the company’s stock.

Guardant Health Price Performance

Shares of Guardant Health stock opened at $131.78 on Friday. The stock’s 50 day simple moving average is $107.23 and its 200-day simple moving average is $102.88. The stock has a market cap of $17.47 billion, a P/E ratio of -38.87 and a beta of 1.61. Guardant Health, Inc. has a 1-year low of $40.35 and a 1-year high of $135.00.

Insider Activity

In other Guardant Health news, Director Meghan V. Joyce sold 10,000 shares of the company’s stock in a transaction on Wednesday, June 3rd. The stock was sold at an average price of $126.98, for a total value of $1,269,800.00. Following the completion of the sale, the director directly owned 11,183 shares in the company, valued at $1,420,017.34. This represents a 47.21% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Amirali Talasaz sold 210,000 shares of the firm’s stock in a transaction on Wednesday, May 20th. The stock was sold at an average price of $109.89, for a total value of $23,076,900.00. Following the completion of the sale, the chief executive officer directly owned 1,886,504 shares of the company’s stock, valued at $207,307,924.56. This trade represents a 10.02% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 449,006 shares of company stock valued at $51,148,938 in the last 90 days. 5.60% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the company. JPMorgan Chase & Co. lifted their price target on Guardant Health from $130.00 to $135.00 and gave the stock an “overweight” rating in a research note on Friday, May 8th. Barclays increased their price objective on Guardant Health from $115.00 to $120.00 and gave the company an “overweight” rating in a research note on Friday, May 8th. Royal Bank Of Canada assumed coverage on Guardant Health in a report on Thursday, June 11th. They issued an “outperform” rating and a $185.00 price objective on the stock. Mizuho raised their price objective on Guardant Health from $135.00 to $175.00 and gave the company an “outperform” rating in a report on Monday, June 8th. Finally, Piper Sandler set a $127.00 target price on shares of Guardant Health in a research note on Thursday, May 21st. One investment analyst has rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $141.95.

About Guardant Health

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.